Prediction of overall survival in patients with pancreatic ductal adenocarcinoma: histogram analysis of ADC value and correlation with pathological intratumoral necrosis

Yoshifumi Noda1*, Hiroyuki Tomita2, Takuma Ishihara3, Yoshiki Tsuboi3, Nobuyuki Kawai1, Masaya Kawaguchi1, Tetsuro Kaga1, Fuminori Hyodo4, Akira Hara2, Avinash R. Kambadakone5 and Masayuki Matsuo1

Abstract

Background: To evaluate the utility of histogram analysis (HA) of apparent diffusion coefficient (ADC) values to predict the overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDAC) and to correlate with pathologically evaluated massive intratumoral necrosis (MITN).

Materials and methods: Thirty-nine patients were included in this retrospective study with surgically resected PDAC who underwent preoperative magnetic resonance imaging. Twelve patients received neoadjuvant chemotherapy. HA on the ADC maps were performed to obtain the tumor HA parameters. Using Cox proportional regression analysis adjusted for age, time-dependent receiver-operating-characteristic (ROC) curve analysis, and Kaplan–Meier estimation, we evaluated the association between HA parameters and OS. The association between prognostic factors and pathologically confirmed MITN was assessed by logistic regression analysis.

Results: The median OS was 19.9 months. The kurtosis ($P < 0.001$), entropy ($P = 0.013$), and energy ($P = 0.04$) were significantly associated with OS. The kurtosis had the highest area under the ROC curve (AUC) for predicting 3-year survival (AUC 0.824) among these three parameters. Between the kurtosis and MITN, the logistic regression model revealed a positive correlation ($P = 0.045$). Lower survival rates occurred in patients with high kurtosis (cutoff value > 2.45) than those with low kurtosis ($\leq 2.45$) ($P < 0.001$: 1-year survival rate, 75.2% versus 100%; 3-year survival rate, 14.7% versus 100%).

Conclusions: HA derived kurtosis obtained from tumor ADC maps might be a potential imaging biomarker for predicting the presence of MITN and OS in patients with PDAC.

Keywords: Diffusion magnetic resonance imaging, Pancreatic cancer, Prognosis

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a 5-year survival rate of only 6% [1]. Surgical resection offers curative remedy; however, only 20% of patients have a resectable tumor at the time of diagnosis. In patients underwent surgical resection, rapid recurrence results in a 5-year relative survival of 39% [2]. Neoadjuvant chemotherapy or chemoradiation therapy...
has been increasingly used in recent years in the preoperative management of patients with borderline resectable or locally advanced PDAC. This has enabled curative surgical resection in a larger cohort of patients [3]. On the other hand, a substantial proportion of patients develop early recurrence or distant metastasis after resection. Therefore, it is important to identify preoperative prognostic factors to determine long term outcome.

Magnetic resonance imaging (MRI) is the preferred imaging modality for the evaluation of liver metastases in patients with PDAC [4]. Apparent diffusion coefficient (ADC) measured with diffusion-weighted imaging allows non-invasive assessment of water diffusion reflecting tissue microstructure [5]. In recent years, ADC histogram analysis (HA) has been investigated as a quantitative imaging biomarker to depict the distribution and frequency of ADC values and therefore determine heterogeneity of water diffusivity within the tumor [6, 7]. This technique has been applied for determining tumor aggressiveness and predicting tumor recurrence in various malignancies such as uterine cervical cancer [8], bladder cancer [9], rectal cancer [10], pancreatic intraductal papillary mucinous neoplasms [11], and pancreatic neuroendocrine tumor [12]. These studies have revealed that certain HA parameters such as kurtosis, 10th percentile, entropy, or skewness could predict pathological complete response or tumor grade. Although, HA on dual-energy CT was used for assessing chemotherapeutic response in patients with PDAC [13], we could not find any literature that performed ADC HA of PDAC.

In patients with PDAC, various imaging features such as hypodensity on CT image at portal venous phase [14], irregular tumor margin [15], and rim enhancement [16] have been reported to be associated with poor prognosis in previous studies. Intratumoral necrosis which is associated with these imaging findings has been reported as a predictor of poor prognosis after surgical resection [17]. Massive intratumoral necrosis (MITN) has been associated with the imaging appearance of rim enhancement with central hypodensity. We hypothesized that HA of ADC maps could be used to determine presence of MITN and therefore help predict patient outcome. Therefore, we undertook this study to evaluate the use of ADC HA to predict the overall survival (OS) and correlate with MITN in patients with PDAC.

Materials and methods

Patients

Seventy-eight consecutive patients with known PDAC based on a previously performed endoscopic ultrasound-guided fine-needle aspiration underwent MRI between February 2015 and March 2020 were included. Thirty-nine out of 78 patients were excluded due to: lack of pathological proof (n = 25) (locally advanced tumor or having distant metastasis [n = 19], scheduled for surgery [n = 5], and rejection of surgery [n = 1]), absence of MRI after neoadjuvant chemotherapy (n = 11), or inability to visualize tumor on MR images (n = 3). The final cohort included 39 patients (mean age, 73.3 ± 7.1 years; age range, 59–84 years) including 18 men (mean age, 74.3 ± 6.4 years; age range, 63–84 years) and 21 women (mean age, 72.5 ± 7.8 years; age range, 59–83 years) (Fig. 1). Out of the 39 patients, 30.8% of patients (n = 12/39) received preoperative neoadjuvant chemotherapy, and 69.2% (n = 27/39) patients underwent upfront surgical resection without neoadjuvant treatment. The neoadjuvant chemotherapeutic regime included: combined gemcitabine and S-1 (n = 6), combined gemcitabine and nab-paclitaxel (PTX) (n = 4), or FOLFIRINOX (folinic acid, fluorouracil, irinotecan, and oxaliplatin) (n = 2). Pancreatoduodenectomy with pancreaticojejunostomy reconstruction was performed in 53.8% (n = 21) and distal pancreatectomy in 46.2% (n = 18). The mean interval between preoperative MRI and pancreatic surgery was 21.8 days (range: 3–81 days). The patient’s medical records were reviewed to document patients’ demographics, plasmatic carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19–9 levels, treatment details, and surgical and pathology reports.

MRI parameters

MRI of the pancreas was performed on a 3 T MR system (Intera Achieva Quasar Dual or Ingenia 3.0 T CX; Philips Medical Systems, Best, the Netherlands) equipped with a 32-channel digital coil. The MRI protocols included the following sequences: three-dimensional fat-suppressed axial T1-weighted fast field echo imaging; in-phase and opposed-phase T1-weighted axial gradient-recalled-echo imaging; respiratory-triggered two-dimensional fat-suppressed axial T2-weighted turbo spin-echo imaging (using Multi-
Vane in Ingenia 3.0T CX); and free-breathing two-dimensional axial diffusion-weighted imaging with a single-shot echo-planar sequence (Table 1).

Gadolinium-enhanced MRI was performed using T1-weighted fat-suppressed sequence (TR/TE, 3.3/1.55 ms; flip angle, 12°; section thickness, 4 mm; slice gap, -2 mm; field of view, 42 x 30 cm; matrix, 304 x 304; and slice number, 90 slices). The patients received one of the following contrast agents: 0.025 mmol gadolinium (Gd)/kg body weight for Gd-EOB-DTPA (0.25 mmol Gd/mL, Primovist®, Bayer HealthCare) or 0.1 mmol Gd/kg body weight for Gd-DTPA (0.5 mmol Gd/mL, Magnevist®, Bayer HealthCare), Gd-BT-DO3A (1.0 mmol Gd/mL, Gadovist®, Bayer HealthCare), Gd-DOTA (0.5 mmol Gd/mL, Magnescope®, Japan), Dotarem®[US], Guerbet), or Gd-DTPA-BMA (0.5 mmol Gd/mL, Omniscan®, GE Healthcare) were administered. Intravenous contrast material administration was performed at a rate of 2 mL/s followed by a 30 mL saline flush at the same rate. Bolus-tracking method was used for performing the multiphasic pancreatic protocol MRI. The arterial dominant and portal venous phases were obtained 10 and 45 s after the detection of contrast in the abdominal aorta, and late-dynamic phases were obtained at 120 s and 180 s after the administration of the contrast material.

**Image analysis**

Two radiologists (Y.N. and N.K., with 10 and 9 years of post-training experience in interpreting abdominal MR images), who were blinded to the clinical information of the patients, reviewed the MR images independently, and then in consensus. Using a commercially available digital imaging software and a Communications in Medicine viewer (ShadeQuest ViewR; Yokogawa Medical Solutions, Tokyo, Japan), which was programmed to perform histogram analyses, the radiologists reviewed the ADC maps. Using a circular region-of-interest (ROI) cursor drawn to encompass as much of the lesion as possible, the radiologists obtained HA parameters on the ADC map with the greatest dimension of PDAC. The ROI placement was performed to include the entire tumors including cystic or necrotic components while carefully avoiding artifacts and flow voids. To determine the precise location of PDAC to enable accurate ROI measurements on the ADC maps, the radiologists were allowed to refer to other MRI sequences. A series of HA parameters were estimated, including mean, standard error, median, mode, standard deviation, variance, skewness, coefficient of variance, minimum, maximum, entropy, and energy.

**Pathological evaluation**

Two experienced pathologists (A.H. and H.T., with 33 and 21 years of experience in tumor pathology, respectively) reviewed the pathological specimens obtained at surgery in consensus. TNM staging was performed according to the eighth edition of the American Joint Committee on Cancer staging system [18] and R classification for tumor differentiation was performed according to the Union for International Cancer Control [19]. Hematoxylin and

| Parameter | Intera Achieva Quasar Dual | Ingenia 3.0T CX |
|-----------|---------------------------|----------------|
| Sequence  | 3D TFE | GRE | 2D TSE | 2D EP |
| Respiratory control | BH | BH | RT | FB |
| Fat suppression | Yes | No | Yes | Yes |
| TR (ms)  | 3.3 | 242 | 1900 | 5000 |
| TE (ms)  | 1.57 | 1.2/2.4/3.6/4.8 | 80 | 63 |
| Flip angle (°) | 15 | 60 | 90 | 90 |
| FOV (cm) | 42 x 30 | 38 x 30 | 38 x 30 | 38 x 30 |
| Matrix | 320 x 224 | 288 x 230 | 512 x 256 | 128 x 128 |
| Parallel imaging factor | 1.5 | 2.2 | 2 | 2 |
| Slice thickness (mm) | 4 | 5 | 5 | 6 |
| Intersection gap (mm) | -2 | 1 | 1 | 0 |
| No. of sections | 90 | 30 | 30 | 30 |
| Acquisition time | 20 s | 21 s | 3 min | 1 min 45 s |
| b values (mm²/s) | NA | NA | 0, 200, 800 | NA |

T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; DWI, diffusion-weighted imaging; 3D, three dimensional; 2D, two dimensional; FFE, fast field-echo; GRE, gradient recalled-echo; TSE, turbo spin-echo; EP, echo-planar; MV, Multi Vane; BH, breath-hold; RT, respiratory-triggered; FB, free-breathing; TR, repetition time; TE, echo time; FOV, field of view; NA, not applicable
eosin-stained specimens were used for the pathological evaluation. Intratumoral necrosis was defined based on its occurrence within the tumor including cancer cells and stroma. For this study, we defined MITN when coagulation necrosis was fully developed according to a previous report [17]. The pathologists evaluated the presence or absence of MITN for each patient.

Statistical analysis
Patients’ demographics and tumor characteristics were summarized using frequencies for categorical variables and mean ± standard deviation (SD) with range for continuous variables. Risk factors associated with OS (from surgery to death) were assessed by Cox proportional hazard model with adjustment for age. One multivariable model includes only two parameters to avoid overfitting, that is, one factor and age. In other words, there are 22 Cox models (9 for patients’ demographics and tumor characteristics, 13 for HA parameters) adjusted for age. Time-dependent receiver operating characteristic (ROC) curve [20] was used to assess the predictive performance of the risk factors strongly associated with OS according to the results using a Cox proportional hazard analysis. The bootstrap bias-corrected area under the ROC curve (AUC) was reported as the measure of the predictive performance of the risk factor. Ten thousand of bootstrap samples were generated and the AUCs obtained from each ROC were averaged to calculate the bootstrap AUC-ROC. An appropriate threshold for predicting mortality was also calculated by averaging the thresholds obtained from each ROC. Cumulative survival rates were estimated using the Kaplan–Meier method for each group separated by the threshold. Differences in survival rates between groups defined by the threshold were confirmed by the log-rank test. To assess the relationship between the risk factor and MITN, logistic regression analysis was performed adjusting for age. All P values of < 0.05 were considered statistically significant. P values were two-sided. P values of < 0.05 were considered statistically significant. All statistical analyses were performed using R version 4.0.2 (www.r-project.org).

Results
Patients’ demographics and tumor characteristics
Patients’ demographics and tumor characteristics are summarized in Table 2. The mean body mass index of the patients was 20.7 ± 3.5 kg/m². Plasmatic CEA and CA 19–9 levels were 4.2 ± 3.7 ng/mL and 285.7 ± 404.7 U/mL, respectively. PDACs were located in the pancreatic head (n = 21), body (n = 11), and tail (n = 7). The mean tumor size was 18.7 ± 5.3 mm. Pathological T classification was 0 in 1 patient, 1c in 9 patients, 2 in 26 patients, and 3 in 3 patients. Pathological N classification was 0 in 15 patients, 1 in 13 patients, and 2 in 11 patients.

| Characteristic | n = 39 |
|----------------|--------|
| **Patients’ demographics** | |
| Age (years) | 73.3 ± 7.1 (59–84) |
| Gender (Male:Female) | 18 (46):21 (54) |
| Body mass index (kg/m²) | 20.7 ± 3.5 (14.9–31.5) |
| CEA (ng/mL) | 4.2 ± 3.7 (0.9–20.2) |
| CA19-9 (U/mL) | 285.7 ± 404.7 (0.1–1818.8) |
| **Tumor characteristics** | |
| Location (head/body/tail) | 21/11/7 |
| Tumor size (mm) | 18.7 ± 5.3 (9.2–30.6) |
| pT stage (0/1a/1b/1c/2/3/4) | 1/0/0/9/26/3/0 |
| pN stage (0/1/2) | 15/13/11 |
| TNM stage (1A/1B/2A/2B/3/4) | 6/9/0/13/11/0 |
| Tumor differentiation (wel/mod/por) | 8/29/2 |
| R classification (0/1) | 33/6 |
| Massive intratumoral necrosis (−/+) | 28/11 |

Data are means ± 1 standard deviation with ranges in parentheses. CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9

R0 resection was achieved in 33 (84.6%). MITN was observed in 11 patients (28.2%).

Analysis of prognostic factors for OS
The median follow-up duration was 15.3 months (range 3.1–47.9). Median OS was 19.9 months, and 23 (59.0%) patients were alive at the last follow-up for data collection. At 1 and 3 years, the estimated OS rates were 84.2% and 45.9%, respectively.

The results of the multivariable Cox proportional hazard analysis of prognostic factors for OS are shown in Table 3. The significant prognostic factors for OS from patients’ demographics and tumor characteristics were tumor location (hazard ratio [HR] [95% lower confidence level and 95% upper confidence level], 1.00 in the pancreatic head, 0.05 [0.01, 0.37] in the pancreatic body, and 0.17 [0.04, 0.70] in the pancreatic tail; P = 0.003), pathological N stage (HR [95% lower confidence level and 95% upper confidence level], 1.00 in pN0, 2.23 [0.59, 8.48] in pN1, and 5.4 [1.46, 20.00] in pN2; P = 0.038), R classification (HR [95% lower confidence level and 95% upper confidence level], 1.00 in R0 and 4.14 [1.42, 12.07] in R1; P = 0.009), whereas those from HA parameters were kurtosis (HR for the 75th vs 25th percentile [95% lower confidence level and 95% upper confidence level], 7.11 [2.42, 20.90]; P < 0.001), entropy (HR for the 75th vs 25th percentile [95% lower confidence level and 95% upper confidence level], 2.06 [1.16, 3.66]; P = 0.013), and energy (HR for the 75th vs 25th percentile [95% lower confidence level and 95% upper confidence level], 0.49 [0.25, 0.97]; P = 0.04). Kurtosis had the strongest association with OS.
among these prognostic factors; therefore, time-dependent ROC curve and bootstrap AUC analyses were conducted for the kurtosis. The cutoff values of the kurtosis for predicting 1- and 3-year survival were 2.83 and 2.45 based on bootstrap AUC. The bootstrap AUCs for predicting 1- and 3-year survival were 0.755 and 0.824 when

| Parameter | HR | 95%LCL | 95%UCL | P value |
|-----------|----|--------|--------|---------|
| Patients' demographics and tumor characteristics | | |
| CEA (ng/mL), IQR 1.70–4.95 | 1.00 | 0.92 | 1.09 | 0.945 |
| CA19-9 (U/mL), IQR 37.55–333.45 | 1.34 | 0.98 | 1.84 | 0.067 |
| Tumor location | | |
| Head | | |
| Body | 0.05 | 0.01 | 0.37 | |
| Tail | 0.17 | 0.04 | 0.7 | |
| Tumor size (mm) | 1.78 | 0.93 | 3.42 | 0.081 |
| pT stage | | |
| 0 | | |
| 1 | 16.82 | 0 | 1.27e+46 | |
| 2 | 83.65 | 0 | 6.21e+46 | |
| 3 | 206.67 | 0 | 1.55e+47 | |
| pN stage | | |
| 0 | | |
| 1 | 2.23 | 0.59 | 8.48 | |
| 2 | 5.4 | 1.46 | 20.0 | |
| TNM stage | | |
| 1A | 1 | | | |
| 1B | 1.69 | 0.17 | 16.4 | |
| 2B | 3.21 | 0.37 | 27.94 | |
| 3 | 7.74 | 0.92 | 65.02 | |
| Tumor differentiation | | |
| Poor | 1.89 | 0.23 | 15.5 | |
| Moderate | 1.34 | 0.11 | 16.24 | |
| Well | | | | |
| R classification | 4.14 | 1.42 | 12.07 | 0.009* |
| Histogram analysis parameters | | |
| Mean, IQR 1320.57–1740.09 | 0.64 | 0.32 | 1.29 | 0.212 |
| Standard error, IQR 17.84–36.08 | 0.63 | 0.32 | 1.24 | 0.183 |
| Median, IQR 1318.04–1720.21 | 0.64 | 0.62 | 1.27 | 0.198 |
| Mode, IQR 1237.17–1586.52 | 0.88 | 0.53 | 1.47 | 0.629 |
| Standard deviation, IQR 96.20–192.00 | 1.02 | 0.56 | 1.86 | 0.941 |
| Variance, IQR 9268.55–36,867.38 | 0.93 | 0.58 | 1.51 | 0.771 |
| Kurtosis, IQR 2.20–3.06 | 7.11 | 2.42 | 20.9 | < 0.001* |
| Skewness, IQR -0.50–0.35 | 0.92 | 0.37 | 2.31 | 0.86 |
| CV, IQR 0.06–0.13 | 1.25 | 0.67 | 2.33 | 0.479 |
| Minimum, IQR 1070.98–1412.84 | 0.62 | 0.35 | 1.11 | 0.107 |
| Maximum, IQR 1626.85–2044.53 | 0.83 | 0.5 | 1.4 | 0.49 |
| Entropy, IQR 1.29–1.56 | 2.06 | 1.16 | 3.66 | 0.013* |
| Energy, IQR 0.03–0.05 | 0.49 | 0.25 | 0.97 | 0.04* |

HR for continuous variable represents the risk of the 75th percentile relative to the 25th percentile. HR for categorical variable is set to 1 for the reference category. e + 46 means 10 to the 46th power. e + 47 means 10 to the 47th power. HR, hazard ratio; LCL, lower confidence limit; UCL, upper confidence limit; IQR, interquartile range (25th-75th percentile); CV, coefficient of variance. *P < 0.05, significant difference.
using these cutoff values (Fig. 2). Patients with high kurtosis (greater than cutoff value) exhibited lower survival rates than those with low kurtosis (cutoff value or less) ($P < 0.001$: 1-year survival rate, 75.2% vs. 100%; 3-year survival rate, 14.7% vs. 100%) (Fig. 3).

**Correlation of the HA parameters with massive intratumoral necrosis**

Logistic regression analysis with adjustment for age demonstrated that the kurtosis was associated with MITN (odds ratio, 4.20; $P = 0.045$) (Fig. 4). In MITN positive cases, the kurtosis was significantly higher than in negative cases (3.10 vs. 2.41; $P = 0.023$) (Figs. 5 and 6). On the other hand, we found no significant correlation in the entropy (odds ratio 1.54; $P = 0.28$) and energy (odds ratio 0.73; $P = 0.37$) with MITN.

**Discussion**

Our study demonstrated that the kurtosis of tumor ADC values obtained from preoperative MR images is an independent prognostic factor for OS in patients with PDAC.
Pathological N stage or R classification were also significant prognostic factors in multivariable Cox proportional hazard analysis; however, these factors are not applicable in the preoperative setting.

HA is a mathematical technique that can evaluate the distribution of gray-level tones on biomedical images and reflects the frequency of pixels exhibiting gray levels that lie within a given interval [21]. HA parameters could reflect information within tumors that cannot be assessed with conventional imaging, including tumor heterogeneity such as necrosis that may represent tumor aggressiveness and prognostic implication [21]. Positive kurtosis means a sharper peak and wider tails. We infer that the reason for patients with high kurtosis exhibiting lower survival rates than those with low kurtosis was due to its association with the heterogeneity of PDAC and presence of hypovascular or hypoxic tissues, and MITN. Hypoxia has been associated with angiogenesis, tumor aggressiveness, and poor prognosis. Generally, the central portion becomes hypoxic, hypo-vascular, and necrotic as the tumor grows [22]. It is believed that these tumors, having MITN, contain large necrotic area in the central portion and a few viable tumor cells in the periphery of the tumor. Therefore, we believe that these tumors show high kurtosis of tumor ADC values. The kurtosis of tumor ADC values was significantly higher in MITN positive cases than in negative cases, as shown in this study, and the kurtosis of tumor ADC values was significantly associated with MITN. In the Cox proportional hazard analysis, entropy and energy showed a significant association with OS as well; however, these parameters were not correlated with MITN. Tumor necrosis has been reported as a prognostic factor in patients with PDAC [14, 16, 17]; however, the presence or absence of tumor necrosis is not preoperatively assessed. We believe that the kurtosis of tumor ADC values could indicate the presence of MITN and could be a prognostic factor in patients with PDAC.

The imaging findings associated with MITN and poor prognosis, including a hypodense tumor in the portal

Fig. 5 A 74-year-old female with pancreatic ductal adenocarcinoma at the tail.  

a Axial arterial phase image and b apparent diffusion coefficient (ADC) map show pancreatic mass with restricted diffusion at pancreatic tail (arrow). The kurtosis of tumor ADC value was 3.1.  
c, d Microphotograph of hematoxylin and eosin-staining for PDAC revealing the massive intratumoral necrosis.
venous phase CT [14] and rim enhancement at dynamic contrast-enhanced MRI [16], were reported in previous studies. Occurrence of MITN in the central portion of PADC reflects a relatively low density/signal intensity area with poor enhancement on dynamic contrast-enhanced imaging and the viable tumor cells in the periphery of the tumor. While these imaging findings are valuable in predicting patients’ outcome, these are subjective imaging appearances. On the contrary, kurtosis of tumor ADC values is an objective and quantitative metric. In 2007, the Quantitative Imaging Biomarker Alliance was established by the Radiological Society of North America to improve the value and practicality of quantitative imaging biomarkers by reducing variability across devices, patients, and time [23]. Our results demonstrate that kurtosis obtained from HA is a quantitative imaging biomarker with profound significance in predicting patients’ OS.

Our study had several limitations. First, this was a retrospective study performed at a single center with a small sample size, which may result in selection bias. The external validation dataset lacks to verify the threshold of kurtosis of tumor ADC values found in this study. Second, to avoid overfitting of the model used in the analysis, we could not consider the removal of biases other than age in confirming the association between OS and predictors. Third, we included both patients who underwent neoadjuvant chemotherapy (n = 12) and surgical resection without neoadjuvant chemotherapy (n = 27). HA and pathological evaluation were performed after neoadjuvant chemotherapy in patients who underwent neoadjuvant chemotherapy. It is perceivable that neoadjuvant chemotherapy caused more MITN compared to patients without neoadjuvant chemotherapy. Our HA and pathological results might be affected by neoadjuvant chemotherapy. Finally, we used various MRI scanners because the study period was relatively long. This might have affected the values of HA parameters; nevertheless, the imaging protocols were standardized. Therefore, further clinical investigations in larger patient cohort

Fig. 6 A 63-year-old female with pancreatic ductal adenocarcinoma at the body. a Axial arterial phase image and b apparent diffusion coefficient (ADC) map show pancreatic mass with restricted diffusion at pancreatic body (arrow). The kurtosis of tumor ADC value was 2.19. c, d Microphotograph of hematoxylin and eosin-staining for PDAC revealing the no massive intratumoral necrosis.
and a homogeneous patient population are needed to validate our results.

Conclusion
In conclusion, the kurtosis of tumor ADC values obtained from HA was associated with MITN and prognosis in patients with PDAC. Therefore, this parameter could be used as a quantitative imaging biomarker for predicting OS.

Abbreviations
ADC: Apparent diffusion coefficient; DWI: Diffusion-weighted imaging; MITN: Massive intratumoral necrosis; MRI: Magnetic resonance imaging; OS: Overall survival; PDAC: Pancreatic ductal adenocarcinoma; HA: Histogram analysis.

Acknowledgements
None.

Authors’ contributions
YN: Guarantor of integrity of the entire study, Study concepts and design, Literature research, Data analysis, and Manuscript preparation; HT: Pathological evaluation, TI: Statistical analysis; YT: Statistical analysis; NK: Literature research and Clinical studies, MK: Pathological evaluation and Clinical studies, TK: Clinical studies; FH: Manuscript editing; AH: Pathological evaluation; AA: Manuscript editing; MM: Manuscript editing. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
This study was approved by the Committee for Medical Ethics, the first affiliated hospital of Gifu University and was performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was waived by the Ethical committee of Gifu University Hospital because of a retrospective study.

Consent for publication
Written informed consent was waived by the Ethical committee of Gifu University Hospital because of a retrospective study.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Radiology, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan. 2Department of Tumor Pathology, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan. 3Innovative and Clinical Research Promotion Center, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Japan. 4Department of Radiology, Frontier Science for Imaging, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan. 5Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA 02114, USA.

Received: 5 October 2021 Accepted: 2 February 2022 Published online: 08 February 2022

References
1. Khoraana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maia A, Mohile SG, Mumber M, Schullick R, Shapiro M, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541–56.
2. National Cancer Institute's Surveillance Epidemiology and End Results Program. Cancer stat facts: pancreatic cancer. 2020. https://seer.cancer.gov/statfacts/html/pancreas.html.
3. Janssen QP, Buettner S, Sukoer M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali WA, Bessellink MG, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111(8):782–94.
4. Noda Y, Goshima S, Takai Y, Kawai N, Kawai N, Kawada H, Tanahashi Y, Matsuo M. Detection of pancreatic ductal adenocarcinoma and liver metastases: comparison of Gd-EOB-DTPA-enhanced MR imaging vs extracellular contrast materials. Abdom Radiol (NY). 2020;45(8):2459–68.
5. Schmid-Tannwald C, Otto A, Reiser MF, Zech CJ. Diffusion-weighted MRI of the abdomen: current value in clinical routine. J Magn Reson Imaging. 2013;37(1):35–47.
6. Bull JG, Saunders DE, Clark CA. Discrimination of paediatric brain tumours using apparent diffusion coefficient histograms. Eur Radiol. 2012;22(2):447–57.
7. Kang Y, Choi SH, Kim YJ, Kim KG, Sohn CH, Kim JH, Yun TJ, Chang KH. Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- and high-b-value diffusion-weighted MR imaging—correlation with tumor grade. Radiology. 2011;261(3):882–90.
8. Downey K, Riches SF, Morgan VA, Giles SL, Attigallle AD, Ind TE, Barton DP, Shepherd JH, deSouza NM. Relationship between imaging biomarkers of stage I cervical cancer and poor-prognosis histologic features: quantitative histogram analysis of diffusion-weighted MR images. AJR Am J Roentgenol. 2013;200(2):314–20.
9. Rosenkrantz AB, Obele C, Rusinek H, Balar AV, Huang WC, Deng FM, Ream JM. Whole-lesion diffusion metrics for assessment of bladder cancer aggressiveness. Abdom Imaging. 2015;40(2):327–32.
10. Cho SH, Kim GC, Jang YJ, Ryeom H, Kim HJ, Shin KM, Park JS, Choi GS, Kim SH. Locally advanced rectal cancer: post-chemoradiotherapy ADC histogram analysis for predicting a complete response. Acta Radiol. 2015;56(9):1042–50.
11. Hoffman DH, Ream JM, Hajdu CH, Rosenkrantz AB. Utility of whole-lesion ADC histogram metrics for assessing the malignant potential of pancreatic intra ductal papillary mucinous neoplasms (IPMNs). Abdom Radiol (NY). 2017;42(4):1222–8.
12. Pereira JA, Rosado E, Bali M, Metens T, Chao SL. Pancreatic neuroendocrine tumors: correlation between histogram analysis of apparent diffusion coefficient maps and tumor grade. Abdom Imaging. 2015;40(8):3122–8.
13. Noda Y, Goshima S, Miyoshi T, Kawada H, Kawai N, Tanahashi Y, Matsuo M. Assessing chemotherapeutic response in pancreatic ductal adenocarcinoma: histogram analysis of iodine concentration and CT number in single-source dual-energy CT. AJR Am J Roentgenol. 2018;211(6):1221–6.
14. Kim DW, Lee SS, Kim SO, Kim JH, Kim HJ, Byun JH, Yoo C, Kim KP, Song KB, Kim SC. Estimating recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma by using pancreatic CT: development and validation of a risk score. Radiology. 2020;296(3):541–51.
15. Noda Y, Goshima S, Tsuji Y, Tomita H, Haru A, Kawauchi M, Kawada H, Kawai N, Tanahashi Y, Matsuo M. Prognostic evaluation of pancreatic ductal adenocarcinoma: Associations between molecular biomarkers and CT imaging findings. Pancreatology. 2019;19(2):331–9.
16. Lee S, Kim SH, Park HK, Jang KT, Hwang JA, Kim S. Pancreatic ductal adenocarcinoma: rim enhancement at MR imaging predicts prognosis after curative resection. Radiology. 2018;288(2):456–66.
17. Hiraoka N, Ino Y, Sekine S, Tsuda H, Shimada K, Kosuge T, Zavada J, Yoshida M, Yamada K, Koyama T, et al. Tumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation. Br J Cancer. 2010;103(7):1057–65.
18. Amin MB, Greene FL, Edge SB, Compton CC, Gershenson JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a
population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.
19. Wittekind C, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer. 2002;94(9):2511–6.
20. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.
21. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–77.
22. Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol. 1999;30(3):198–205.
23. Jackson EF. Quantitative imaging: the translation from research tool to clinical practice. Radiology. 2018;286(2):499–501.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.